Biosimilar butterflies and myths
This article was originally published in Scrip
As the biosimilars debate in the United States gains momentum, some new data from Gaucher's and Fabry's diseases patients receiving replacements for their enzyme deficiency ought, in a logical world, to quieten some elements. It probably won’t though.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.